(Q34238077)

31 July 2017

1 reference

title

Experimental models of Parkinson's disease (English)

1 reference

31 July 2017

1 reference

Beal MF

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

Nature Reviews Neuroscience

31 July 2017

published in

1 reference

31 July 2017

volume

2

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

325-334

1 reference

https://scigraph.springernature.com/pub.10.1038/35072550

31 July 2017

exact match

0 references

cites work

Parkinson's disease. First of two parts

1 reference

7 January 2021

Parkinson's disease. Second of two parts

1 reference

7 January 2021

The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living

1 reference

7 January 2021

Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany.

1 reference

7 January 2021

Familial Aggregation of Parkinson's Disease in Iceland

1 reference

7 January 2021

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

1 reference

7 January 2021

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

1 reference

7 January 2021

Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat.

1 reference

7 January 2021

Parkinson's disease, pesticides, and glutathione transferase polymorphisms

1 reference

7 January 2021

Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group

1 reference

7 January 2021

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

1 reference

7 January 2021

Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies

1 reference

7 January 2021

A Drosophila model of Parkinson's disease

1 reference

7 January 2021

Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system

1 reference

7 January 2021

Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders

1 reference

7 January 2021

Neuropathology in mice expressing human alpha-synuclein

1 reference

7 January 2021

The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease

1 reference

7 January 2021

Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter.

1 reference

7 January 2021

VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity

1 reference

7 January 2021

Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds

1 reference

7 January 2021

Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain

1 reference

7 January 2021

Manganese superoxide dismutase overexpression attenuates MPTP toxicity.

1 reference

7 January 2021

Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity

1 reference

7 January 2021

Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP.

1 reference

7 January 2021

Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity

1 reference

7 January 2021

Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o'-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease.

1 reference

7 January 2021

Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice.

1 reference

7 January 2021

Protein nitration in Parkinson's disease.

1 reference

7 January 2021

Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.

1 reference

7 January 2021

S-Methylthiocitrulline, a neuronal nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity

1 reference

7 January 2021

Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity

1 reference

7 January 2021

Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo

1 reference

7 January 2021

Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease

1 reference

7 January 2021

Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide.

1 reference

7 January 2021

Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism

1 reference

7 January 2021

Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity

1 reference

7 January 2021

A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

1 reference

7 January 2021

Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease

1 reference

7 January 2021

Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.

1 reference

7 January 2021

An electron microscopic study of MPTP-induced inclusion bodies in an old monkey

1 reference

7 January 2021

Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.

1 reference

7 January 2021

Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease.

1 reference

7 January 2021

Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons.

1 reference

7 January 2021

Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

1 reference

7 January 2021

Reversal of experimental parkinsonism by lesions of the subthalamic nucleus

1 reference

7 January 2021

Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates

1 reference

7 January 2021

In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining

1 reference

7 January 2021

Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease.

1 reference

7 January 2021

Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease

1 reference

7 January 2021

Cell death and apoptosis regulating proteins in Parkinson's disease--a cautionary note.

1 reference

7 January 2021

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2.

1 reference

7 January 2021

Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity

1 reference

7 January 2021

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.

1 reference

7 January 2021

Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

1 reference

7 January 2021

Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

1 reference

7 January 2021

Dopamine neurons from transgenic mice with a knockout of the p53 gene resist MPTP neurotoxicity

1 reference

7 January 2021

MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo

1 reference

7 January 2021

CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.

1 reference

7 January 2021

Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure

1 reference

7 January 2021

The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse.

1 reference

7 January 2021

Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease

1 reference

7 January 2021

Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity.

1 reference

7 January 2021

Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice

1 reference

7 January 2021

Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity

1 reference

7 January 2021

NMDA antagonists partially protect against MPTP induced neurotoxicity in mice

1 reference

7 January 2021

The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates

1 reference

7 January 2021

MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates.

1 reference

7 January 2021

Protection against acute MPTP-induced dopamine depletion in mice by adenosine A1 agonist.

1 reference

7 January 2021

Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study

1 reference

7 January 2021

Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.

1 reference

7 January 2021

Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice

1 reference

7 January 2021

The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease

1 reference

7 January 2021

Novel free radical spin traps protect against malonate and MPTP neurotoxicity.

1 reference

7 January 2021

Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice.

1 reference

7 January 2021

Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production

1 reference

7 January 2021

Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets

1 reference

7 January 2021

Functional recovery in parkinsonian monkeys treated with GDNF

1 reference

7 January 2021

Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo

1 reference

7 January 2021

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

1 reference

7 January 2021

A novel immunophilin ligand: distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease.

1 reference

7 January 2021

Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models

1 reference

7 January 2021

Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates.

1 reference

7 January 2021

Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice.

1 reference

7 January 2021

Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects.

1 reference

7 January 2021

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

1 reference

7 January 2021

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

1 reference

7 January 2021

Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro

1 reference

7 January 2021

Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase

1 reference

7 January 2021

Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.

1 reference

7 January 2021

Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease

1 reference

7 January 2021

alpha-synuclein promotes mitochondrial deficit and oxidative stress

1 reference

7 January 2021

Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult

1 reference

7 January 2021

The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism

1 reference

7 January 2021

Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates

1 reference

7 January 2021

Stereotactic pallidotomy in the treatment of Parkinson disease: an expert opinion

1 reference

7 January 2021

Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease

1 reference

7 January 2021

Neuropathology of Parkinson's disease

1 reference

7 January 2021

Identifiers

DOI

10.1038/35072550

1 reference

Dimensions Publication ID

31 July 2017

1050001570

0 references

1 reference